Eqitx to raise $1.8 million

By Melissa Trudinger
Tuesday, 07 December, 2004

Melbourne-based biotech managed investment group EQiTX (ASX: EQX) will ask shareholders to approve a AUD$1.8 million capital raising to provide working capital for its two projects ZingoTX and VacTX.

The placement, involving the issue of six million new shares at $0.30 plus two million free attaching options with an exercise price of $0.20, is to be underwritten by Cunningham Securities.

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Content from other channels on our network

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Sustainable wastewater treatment achieved for urban areas

'Brownfielding' increases to meet metal demand

NSW to exceed energy storage targets

Gilmour Space opens office in South Australia

Myriota launches satellite global asset tracking

Cyber risk is rising faster than Australian manufacturers can respond

Fortescue commissions first battery electric locomotives

Electric actuation: a gamechanger for upstream processes

Why physical device security is becoming a patient privacy issue in health care

Food waste in Australian hospitals and aged care homes — can AI help?

Legislation introduced to improve private health choice and transparency

WA healthcare professionals gain workplace-specific courses

InterSystems Honoured with Four 2026 Best in KLAS Awards